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7.1
Staging of metastatic malignant melanoma with IODINE-123-IMB
scintigraphy
V. Waldmanuo , M. Flesch2, A. Jackel', A. Mohaimed2, C. Nicholl. B. Bubeck2, M. Bock'.
M. Deichmanu1, H. Naher'. M. Eisenihut., 'Dept. ofDermatology. Inst. of Nuclear Mediciine.
Uiuversity ofHeidelberg, Germaniy
75% of all metastases from melanoma occure in the first 5 years
after primary surgical therapy. This indicates the importance of
follow-up for melanoma patients in the first years after primary
therapy. The development of an effective scintigraphic method to
detect specifically vital melanoma metastases irrespectively from
their location through the body has been a research goal for some
time. A recently synthesized radioiodinated IMBA, N-(2-
diethyldiaminoethyl))-3-['231I]iodo-4-methoxybenzamide, promised
high scintigraphic efficacy specific to melanoma (Nicholl et al., J
Nucl Med 38, 127-33, 1997). Here we report the examination of8
patients with histologically proven metastatic melanoma. We
applied 200-300 Mbq of radioiodinated IMBA intravenously. 1
min, 1, 4 and 20 hr p.i. whole body scans were performed. Visually
the early organ uptake of radioiodinated IMBA is dependent on
perfusion in heart, lung, liver, spleen, kidney, brain and thyroid.
The high initial uptake of lungs and liver results in a delayed
visualization of metastases in these organs. Metastases of lymph
nodes and extremities are detectable much earlier. In some patients
we were able to see previously unknown metastases. These
preliminary results and the high imaging contrast for localizing
small metastases throughout the body offer considerable potential
for improved melanoma imaging in patients.
7.3
Increased sensitivity in early detection of submicroscopic
lymph node metastases in melanoma patients
C. Voit, A. Schoengen', R.U. Peter, Dept. of Dermatology, 'Dept. of
Internal Medicine, University ofUrm, Germany
Purpose: Diagnostic exstirpation of suspicious lymph nodes in
melanoma patients often had servere side effects. Sonographically
directed fine needle aspiration cytology (FNAC) is a method free of
complications to identify metastases, but may fail in cases of small
lesions. Therefore we investigated, whether combination of fine needle
aspiration and PCR (FNA-PCR) to identify tyrosinase mRNA specific
for melanoma cells could increase sensitivity.
Patients and methods: We performed fine needle aspirations of 88
lymph nodes in the draining site of melanoma and 15 lymph nodes of
control patients with inflammatory disesases or nonmelanoma neoplasms.
In addition we analyzed blood samples of these patients to identify
circulating melanoma cells.
Results: In 40 lymph nodes histopathological examination was positive
for melanoma metastases. FNAC achieved a sensitivity of 90%, whereas
FNA-PCR showed a sensitivity of 95%. However, in the subgroup of
small metastases (<10mm) FNAC achieved a sensitivity of 71%, while
FNA-PCR had a sensitivity of 100%. 48 patients had unspecific altered
reactive lymph nodes detected by ultrasound. In all cases FNAC was
negative, while FNA-PCR was positive in 2 of 48. 15 control patients
were negative. Tyrosinase-blood-PCR was positive in 0% (stage I) and
29% (stage H) of patients with localized disease, 52% of patients with
lymph node metastases (stage [H) and 90% of patients with distant
metastases. 71% of patients were blood-PCR positiv, while only 27%
were blood-PCR negative at time ofrelapse.
Conclusions: We conclude, that FNA-PCR has a very high sensitivity in
early detection of melanotic lymph node metastases. Furthermore
tyrosinase-PCR from peripheral blood is an important marker for
systemic tumor progression in melanoma patients.
7.2
Thallium-201 whole body imaging in patients with malignant melanoma
W. Brenner, H.-J. Klomp', K.H. Bohuslavizld, B. Szonn, E. Henze, Dept. of
Nuclear Medicine, 'Dept. ofSurgery, University ofKiel, Gennany
Thallium-201 has been proven useful for imaging of primary or
metastatic lesions in various tumours. The aim of this study was to
investigate the diagnostic value ofT1-201 in melanoma patients.
150 MBq TI-201 was administered intravenously to 30 patients with
metastatic melanoma prior to surgical therapy. Whole body
scintigrams were acquired 5 and 30 min p.i..
34 out of 39 lesions histologically proven were true positive
corresponding to a sensitivity of 87%. Four in-transit metastases and
one inguinal lymph node metastasis in the contralateral groin which
were not known at the time of investigation despite a complete
diagnostic work-up including CT were found only by TI-201 imaging.
Due to these additional scintigraphic findings the surgical procedure
was extended significantly in three patients. On the other hand, T1-201
imaging was false negative in four lymph node metastases and one
skin metastasis. Furthermore, T1-201 imaging was true negative in one
patient with an inguinal hematoma, and there were two false positive
scanswith tracer accumulation in inflammatory lesions.
In conclusion, T1-201 whole body imaging is a sensitive and easy-to-
perform method for detecting lymph node metastases in patients with
malignant melanoma which yielded a change to the scheduled surgical
procedure in 3 of30 patients.
7.4
Malignant melanoma: How useful are tumor markers in the
detection of hematogeneous metastasis?
A. Hauschild, E. Stockfleth, R. Glaser, E. Christophers, Dept. of
Dermatology, University ofKiel, Germany
Despite great efforts during recent years to develop markers for detection of
melanoma cells so far no serum marker has reached an accepted status in the
clinical guidelines. However, very recently several groups presented
interesting new data indicating major advances in this field.
We could demonstrate in a study on more than 400 melanoma patients (stage
I-IV) that the detection ofserum S1OOI (Sangtec; Sweden) is a reliable marker
for advanced disease. 68% of stage IV-disease patients were S100-positive and
furthermore, survival was predictable according to the S100-levels (median
survival for patient, with SIO0 < 0,2 gg/l: 14 months; 0.2 il/I to < 0,6 jg/l: 9
months; > 3,0 p.g/l: 4 months).
Monitoring ofstage IV-disease during treatment revealed that tumor shrinkage
was paralleled by declining levels whereas patients with tumor progression
showed increasing serum S100-levels reflecting the natural course ofdisease.
The serum detection of 5-S-Cysteinyl-DOPA (5-S-CD) has been
controversially discussed due to several technical pitfalls. We have now
developed a new optimized HPLC-method. In a pilot study with 75 melanoma
patients 5-S-CD proved to be a sensitive marker for metastatic disease with the
majority ofpatients being 5-S-CD-positive.
On the other hand a broad variety of other markers revealed dissatisfying
results concerning sensitivity and specificity in our lab. As an example
tyrosinase-PCR was found to be positive in only 29% of advanced metastatic
melanoma patients. Also, neither antibodies against the tumor suppressor gene
p53 nor adhesion molecules like ICAM-1 or CD44 v6 were sensitive and
specific enough to serve as a routine marker.
These data demonstrate, that at present only the detection of serum SI00R has
proved to be of relevance in the daily routine. 5-S-CD is a hopeful candidate
for further analysis. We started a prospective study on the use of S1QOB, 5-S-
CD and the recently described ,,melanoma inhibiting activity (MIA)" in the
monitoring and follow-up ofmelanoma patients.30 Malignant melanoma
7.5
Serum-S100: A tumor marker for melanoma metastasis
P. Kaskel', A. Nolte2, R.U. Peter', G. Krahn', 'Dept. of Dermatology,
University of Ulm, 2Dept. of Dermatology, University of Munich,
Germany
S100 protein is frequently used in histopathological staining of
melanoma. Recent data indicate that serum-S100 levels correlate
with melanoma progression.The aim ofthis study was to evaluate
serum-S100 as a tumor marker in melanoma patients. Applying a
two-site immuno-radiometric (Sangtec 100* IRMA) and a
immuno-luiminometric (Sangtec 100l LIA) assay, serum-S100
levels in 286 samples of 219 patients including 43 controls were
measured. Using RIA technique (cut-off level l,Opg/l; sensitivity
77%), 87% of patients with visceral lymph node and cerebral
metastases showed elevated levels. 50% of cutaneous metastases,
97% ofprimary melanomas and 95% ofcontrols werenegative.
With LIAtechnique (cut-offlevel 0,12 gg/l; sensitivity 86%) 92%
ofpatients with visceraL lymph node and cerebral metastases and
67% of cutaneous metastases were positive. 93% of primary
melanomas and 93% ofcontrols werenegative.
RlA/LIA-results with special respect to head and neck tumors will
be discussed. Follow-up of 27 selected cases with progression
showed that serum-S100 measurement might be a reliable marker
in monitoring ofthe course ofthe disease.
These data indicate that serum-S100 may well serve as a tumor
marker for malignant melanoma in case ofprogression and as a
marker to monitortherapeutic results.
7.7
Epifocal immunotherapy with DNCB combined with systemic
DTIC-chemotherapy is a well tolerated, inexpensive and effective treatment of
metastatic melanoma
J. Trcka, E. Kimpgen, J.C. Becker, E.B. Brocker, Dept. ofDermatology, University of
Wirzburg, Germany
Chemotherapy of metastatic melanoma rarely results in long-lasting
remissions or prolongation of life. Cytokine-based
(chemo)immunotherapy, though inducing durable remissions in some
patients, bears the risk of severe side effects and is very costly. Thus,
stimulated by Rumke (Medicographia 14:47,1992) who observed a 22%
complete response (CR) rate by epifocal application of the contact
allergen dinitrochlorobenzene (DNCB) over cutaneous metastases if
combined with systemic dacarbazine(DTIC), wetested a similar regimen
in 24patients.
Monthly DTIC boluses (850 mg/m2) were combined with weekly
epifocal applications of DNCB at a concentration (0.1-1% in vaseline)
which maintained a brisk contact eczema. 15 patients which completed at
least 2cycles ofcombined treatment and were followed fore more than 4
months were evaluated. In two patients metastases were restricted to the
skin, whereas 13 patients suffered also from lymphnode-, or visceral
metastases.
We observed 4 CRwhich lasted up to 36 months and 3 partial remissions
of4, 5+, and 8 months. Interestingly, 6 oftheseremissions were seen in 7
previously untreated.patients. Besides itching from eczema, neither
hematological side effects nor cutaneous unresponsiveness to DNCB
during DTICchemotherapy were observed.
Our data demonstrate that the immunochemotherapy with epifocally
applied DNCB on cutaneous metastases combined with intravenous
DTIC=20 (I.) is a well-tolerated and effective treatment of metastatic
melanoma,=20 (11.)is more amenable as a first line therapy for
previously untreated patients with intact immune systems,=20 (HI.) and
furthermore, is a low cost therapy that requires only minimal
hospitalization and barely interferes with thepatients quality oflife.
7.6
Treatment of metastatic malignant melanoma with DTIC, Cisplatin, BCNU,
and Tamoxifen followed by immunotherapy with IL-2 and IFN-alpha
K. Neuberl, H. Kirchner, J. Atzpodien2, 'Dept. of Dermatology, University of
Hamburg, 2Dept. ofHematology and Oncology, Medical School Hannover, Germany
It was the purpose of this study to determine response rates, Freedom
From Treatment Failure (FFTF) and overall survival in patients with
advanced metastatic malignant melanoma treated with combined chemo-
/immunotherapy and to determine the value of a prognostic model for
prediction oftreatment outcome, FFTF, and survival. Sixty-nine patients
with metastatic malignant melanoma received combined chemo-/immuno-
therapy consisting ofup to 4 cycles of DTIC (220 mg/mi2 iv days 1 to 3>,
cisplatin (35 mg/m2 iv days 1 to 3), BCNU (150 mg/M2 iv day 1, cycles I
and 3 only) and tamoxifen (20 mg oral daily). Two cycles of
chemotherapy were followed by 6 weeks of outpatient immunotherapy
with combined Interleukin-2 (20 Mio. IU/M2 sc days 3-5, wk 1 and 4; 5
Mio. IU/m2 days 1, 3, 5 wks 2, 3, 5, 6) and Interferon-c (6 Mio. IU/M2 sc
day 1, wk 1 and 4; days 1, 3, 5 wks 2, 3, 5, 6). All patients were
evaluated on an intend-to-treat-basis. Of 69 patients entered in the study,
seven achieved complete remissions and 20 reached partial remissions
with an objective response rate of 39%. Median survival was eleven
months, median FFTF was 5 months. A small proportion of patients
achieved long-term remissions, with maximum survival of 55+ and
maximum FFTF of 52+ months. By Kaplan-Meier survival analysis and
two-proportional Cox regression analysis, pretreatment performance
status and serum lactic dehydrogenase were statistically significant and
independent predictors ofsurvival; riskgroups could be defined as (a) the
absence of both, or (b) the presence of either one or both of these risk
factors. While survival was significantly influenced by patients risk, no
influence could be demonstrated for FFTF. Combined chemo-
/immunotherapy results in high objective response rates and leads to
prolonged overall survival and FFTF when compared to historic control
patients.
7.8
Hyperthermia as adjuvant therapy for metastatic malignant
melanoma of the skin
R. Hofmann-Wellenhof, E. Richtig, W. Amann, M. Hoff, J. Smolle, H.
Kerl, Dept. ofDermatology, University ofGraz, Austria
Therapy of metastatic melanoma remains unsatisfying. Thus
palliative therapeutic modalities become more important. Local
hyperthermia in combination with radiation and/or chemotherapy
has been proven to be ofbenefitin reducing tumour masses and for
local tumour control. We used local hyperthermia in 21 patients
(10 male, 11 female) with malignant melanoma ofthe skin. The
mean age was 46.8 years (range 27-77 years). 10 patientshad local
metastases and 11I had distant metastases. Six metastatic lymph
node regions (1 cervical, 2 paravisceral, 3 inguinal) and 15 areas
extensive cutan-subcutaneus metastases. Hyperthermia was
combined in 15 patients with chemotherapy and radiation, in 2
patients only with radiation, and 5 patients only with
chemotherapy. Hyperthermia was well tolerated by most of the
patients. Fourpatients showed a complete response, and 8 patients
showed a partial response. In 6 patients local tumour control was
achieved. In 3 patients progressive disease was observed.
Hyperthermia in combination with chemotherapy and/or radiation
improves the local treatment ofpatients with distant metastases of
malignant melanoma.Malignant melanoma 31
7.9
Melanoma associated antigens: the development of novel
immuno- and genetherapeutic strategies in melanoma patients
S.N. Wagner, Dept. of Dermatology, University of Essen, Germany
Autologous tumor cells can be recognized by CTL via cell-surface
expression of tumor associated antigens. Enhanced expression of
these antigens may increase immunogenicity of tumor cells, while
elimination of genes coding for these antigens can lead to
diminished or absent immunogenicity. Regression-associated
depigmentation or development of vitiligo in melanoma patients
indicates that differentiation antigens seem to constitute a
particularly relevant subgroup of melanoma associated antigens
(MAA). MAA Pmel17/gp100 has been identified to encode several
epitopes recognized by melanoma specific CTL. Its highly
conserved expression in all stages of melanoma tumor progression
with differential expression between melanoma cells and normal
melanocytes indicates that Pmel 17/gp100 may behave as a
melanoma-specific antigen in vivo. Tumor regression after adoptive
transfer or Pmell7/gplOO-reactive CTL lines or intradermal
vaccination with Pmel17/gpO00 peptides in melanoma patients and
protection of mice immunized with a Pmel 17/gpO00 DNA vaccine
against melanoma challenge emphasize the potential therapeutic
impact of this MAA. Furthermore, the identification of shared
Pmel 17/gp100-encoded epitopes and presentation of
Pmel17/gp100-encoded epitopes by HLA-A1, -A2, and -A3, allow
the application of Pmel17/gp1OO-targeted immuno- and/or
genetherapies to a broad spectrum of melanoma patients.
7.10
Primary sinonasal melanomas. A clinicopathological study
S. Regauer, W. Anderhuber', E. Richtig2, J. Schachenreiter', A. Ott, A.
Beham, Dept. of Pathology, 'Dept. of. ORL, 'Dept. of Dermatologv.
University ofGraz, 'Elisabethinen Hospital, Austnra
We present 14 patients with primary sinonasal melanomas (SM).
8M/6F, mean age 67 years at presentation, age range 39 - 88
years, 1 1/14 arising in the lower and middle conchae, 2/14 in the
frontal sinuses and 1/14 in the nasal septum. In the adopted TNM
classification system for cancer ofthe nose and paranasal sinuses,
12/14 SM were classified as T3 or 4, and one each was Tl and T2
at time of diagnosis with only one patient having a (brain)
metastasis. The cervical lymph nodes were negative in all patients
("certainty factor"' C I or C2 in the TNM classification system). At
present. 3 patients are alive withl disease (6, 9 and 31 months
resp.). Survival was poor with an average of 18 months, range 3-
76 months, independent of histological subtypes and aggressive
therapy including surgery, radiation and chemotherapy. Tumor
stage at presentation appeared to be the only progtnostic
parameter. Hematogenous distant metastases were identified in
10/14 patients during follow-up (,,certainty factor" Cl or C2) in
abdominal organs and cavity, lung and brain. Death was related to
extensive primary and/or recurrent local disease and/or widespread
hematogenous metastases. Regional lymph node metastases were
not identified but in one patient.
7.12
Lymphatic spread of mucosal melanomas
J.G. Batsakis, Dept. ofPathology, M.D. Anderson Cancer Center,
Houston, U.S.A
Among Caucasians a rather constant percent of all melanomas
arise in noiiocular mucous membranes. A rather constant
percentage also takes origin in the oral cavity and upper
respiratory tract - 6-7.5%. Although the reported number ofcases
is small, those ofthe upper airway exceed those ofthe oral cavity
and yet the biologic course is better detailed for the oral cavity.
This report will present a M.D. Anderson series of 42 evaluated
patients between 1944 - 1989 with upper aerodigestive tract
melanomas and compare those data with the literature's with
reference to lymphatic metastases. Nearly 80% oforal melanomas
arise in the mucosa ofthe upperjaw (usually keratinizing). Nearly
one-half ofthese melanomas will have regional metastasis (Stage
II). Seventy percent of Stage I and 83% of Stage II oral
melanomas have a tumor thickness greater than 4.0 mm. A
thickness greater than 5 mm is likely to be associated with regional
node metastases. The most common sites ofnodal involvement are
the same as for oral squamous cell carcinoma; submandibular and
upperjugular. Node involvement is inconsistently related to distant
spread. It also appears that the pattern of lymphatic spread of
sinonasal melanomas also follows that of squamous carcinoma,
especially when there is secondary extension into the oral cavity. In
the M.D. Anderson cohort, status ofregional nodes did not appear
to affect survival. Lymphatic spread from aerodigestive sites may
predispose to distant spread but disseminated disease is more
capricious.